Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells – implications for systemic control

Patients with high-grade prostate cancer (PCa) are at significant risk for local and distant relapse post treatment. High dose rate brachytherapy (BT) may improve PCa-specific survival and distant metastasis-free survival (DMFS) compared to external beam radiotherapy (EBRT) in conjunction with androgen deprivation therapy (ADT) in Gleason (Gl) 9-10 patients[1,2]. This suggests that BT, despite being a local treatment, may potentially induce immune activation resulting in enhanced systemic control.

Source: Radiotherapy and Oncology - January 1, 2024 Category: Radiology Authors: H. Wang, L. Mendez, G. Morton, A. Loblaw, H.T. Chung, P. Cheung, A. Mesci, V. Escueta, T.N. Petchiny, X. Huang, S.D. White, M. Downes, D. Vesprini, S.K. Liu Tags: Short Communication Source Type: research